Amarin Corp. PLC ADR (AMRN): Price and Financial Metrics

Amarin Corp. PLC ADR (AMRN): $3.36

-0.16 (-4.55%)

POWR Rating

Component Grades













Add AMRN to Watchlist
Sign Up

Industry: Biotech


of 465

in industry


  • AMRN scores best on the Value dimension, with a Value rank ahead of 91.98% of US stocks.
  • AMRN's strongest trending metric is Quality; it's been moving down over the last 157 days.
  • AMRN ranks lowest in Momentum; there it ranks in the 9th percentile.

AMRN Stock Summary

  • AMRN's one year PEG ratio, measuring expected growth in earnings next year relative to current common stock price is 460.51 -- higher than 94.28% of US-listed equities with positive expected earnings growth.
  • For AMRN, its debt to operating expenses ratio is greater than that reported by merely 6.89% of US equities we're observing.
  • With a year-over-year growth in debt of -53.38%, Amarin Corp Plc's debt growth rate surpasses just 8.39% of about US stocks.
  • Stocks that are quantitatively similar to AMRN, based on their financial statements, market capitalization, and price volatility, are TREC, EVOP, QBAK, PODD, and SRTS.
  • AMRN's SEC filings can be seen here. And to visit Amarin Corp Plc's official web site, go to

AMRN Valuation Summary

  • AMRN's price/sales ratio is 3.5; this is 69.16% lower than that of the median Healthcare stock.
  • Over the past 130 months, AMRN's EV/EBIT ratio has gone up 152.5.
  • Over the past 130 months, AMRN's price/sales ratio has gone NA NA.

Below are key valuation metrics over time for AMRN.

Stock Date P/S P/B P/E EV/EBIT
AMRN 2021-08-31 3.5 3.3 497.8 148.5
AMRN 2021-08-30 3.5 3.4 506.9 151.7
AMRN 2021-08-27 3.6 3.4 514.3 154.2
AMRN 2021-08-26 3.6 3.5 517.0 155.2
AMRN 2021-08-25 3.7 3.6 534.4 161.3
AMRN 2021-08-24 3.7 3.5 528.0 159.1

AMRN Growth Metrics

    Its 3 year net income to common stockholders growth rate is now at 20.47%.
  • Its 5 year price growth rate is now at 361.21%.
  • Its year over year net cashflow from operations growth rate is now at -235.69%.
Over the past 33 months, AMRN's revenue has gone up $376,733,000.

The table below shows AMRN's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-09-30 605.947 -76.62 -2.043
2021-06-30 620.408 -61.227 4.32
2021-03-31 601.237 -44.587 0.927
2020-12-31 614.06 -21.746 -18
2020-09-30 590.086 7.641 -15.858
2020-06-30 545.995 18.538 -12.532

AMRN's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • AMRN has a Quality Grade of B, ranking ahead of 81.41% of graded US stocks.
  • AMRN's asset turnover comes in at 0.626 -- ranking 51st of 680 Pharmaceutical Products stocks.
  • CEMI, NEOG, and INSM are the stocks whose asset turnover ratios are most correlated with AMRN.

The table below shows AMRN's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.626 0.793 0.031
2021-03-31 0.628 0.792 0.019
2020-12-31 0.652 0.786 -0.036
2020-09-30 0.641 0.784 -0.042
2020-06-30 0.608 0.781 -0.052
2020-03-31 0.668 0.778 -0.163

AMRN Stock Price Chart Interactive Chart >

Price chart for AMRN

AMRN Price/Volume Stats

Current price $3.36 52-week high $9.25
Prev. close $3.52 52-week low $3.11
Day low $3.35 Volume 6,644,872
Day high $3.59 Avg. volume 3,320,236
50-day MA $3.60 Dividend yield N/A
200-day MA $4.57 Market Cap 1.33B

Amarin Corp. PLC ADR (AMRN) Company Bio

Amarin Corporation plc, a biopharmaceutical company, focuses on developing and commercializing therapeutics for the treatment of cardiovascular diseases in the United States. The company was founded in 1989 and is based in Dublin, Ireland.

AMRN Latest News Stream

Event/Time News Detail
Loading, please wait...

AMRN Latest Social Stream

Loading social stream, please wait...

View Full AMRN Social Stream

Latest AMRN News From Around the Web

Below are the latest news stories about Amarin Corp Plc that investors may wish to consider to help them evaluate AMRN as an investment opportunity.

Amarin Corporation plc (AMRN) Fell Out Of Favor With Hedge Funds?

As we already know from media reports and hedge fund investor letters, hedge funds delivered their best returns in a decade. Most investors who decided to stick with hedge funds after a rough 2018 recouped their losses by the end of the fourth quarter of 2019. A significant number of hedge funds continued their strong […]

Yahoo | January 12, 2022

Hikari Power Ltd Buys Alphabet Inc, Vanguard Health Care ETF, Bristol-Myers Squibb Co, Sells ...

Tokyo, M0, based Investment company Hikari Power Ltd (Current Portfolio) buys Alphabet Inc, Vanguard Health Care ETF, Bristol-Myers Squibb Co, Jack Henry & Associates Inc, Parker Hannifin Corp, sells Anheuser-Busch InBev SA/NV, The Kraft Heinz Co, Amarin Corp PLC, ADMA Biologics Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Hikari Power Ltd.

Yahoo | January 12, 2022

Amarin Corporation plc (AMRN) CEO Karim Mikhail Presents at 40th Annual J.P. Morgan Healthcare Conference (Transcript)

Amarin Corporation plc (AMRN) 40th Annual J.P. Morgan Healthcare Conference January 11, 2022 8:15 AM ET Company Participants Karim Mikhail - President, CEO & Director Conference Call Participants Jessica Fye - JPMorgan Chase & Co. Presentation Jessica Fye Hey, good morning, everyone. My name is Jess Fye. I'm one of...

SA Transcripts on Seeking Alpha | January 11, 2022

Amarin Provides Preliminary 2021 Revenue and Outlook for 2022

DUBLIN, Ireland and BRIDGEWATER, N.J., Jan. 10, 2022 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today provided a business update, including preliminary unaudited full-year 2021 revenue results. Amarin plans to discuss these results and expectations with investors in connection with the 40th Annual J.P. Morgan Healthcare Conference at which Amarin is scheduled to present virtually on Tuesday, January 11, 2022, at 8:15 am Eastern time. Preliminary (Unaudited) 2021 Financial Results R

Yahoo | January 10, 2022

Amarin to Present at the 40th Annual J.P. Morgan Healthcare Conference

DUBLIN, Ireland and BRIDGEWATER, N.J., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN) today announced that Karim Mikhail, president and chief executive officer of Amarin, is scheduled to present virtually at the 40th Annual J.P. Morgan Healthcare Conference on Tuesday, January 11, 2022, at 8:15 am ET. A live webcast of the presentation will be accessible under Events in the Investor Relations section of the company’s website at

Yahoo | January 4, 2022

Read More 'AMRN' Stories Here

AMRN Price Returns

1-mo -3.17%
3-mo -33.20%
6-mo -18.45%
1-year N/A
3-year -80.50%
5-year 16.67%
YTD -0.30%
2021 -31.08%
2020 -77.19%
2019 57.53%
2018 239.40%
2017 30.19%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.7902 seconds.